Patients with metastatic castration-resistant prostate cancer who received Lu-177-PSMA-617 (Pluvicto) achieved similar overall survival and had fewer serious adverse events compared to those who ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback